SpringWorks Therapeutics Inc. has completed its merger transaction, as outlined in a recent Form 8-K filing. As a result of the merger, each share of SpringWorks' common stock was automatically converted into the right to receive $47.00 in cash, minus applicable taxes. Additionally, vested stock options were canceled, entitling holders to cash payments based on the difference between the merger consideration and the exercise price. Restricted stock unit awards, whether vested or not, have been converted into cash-based awards, with a portion of unvested awards set to vest nine months post-transaction, contingent on continued employment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SpringWorks Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-064445), on July 01, 2025, and is solely responsible for the information contained therein.